New ALS drug prosetin enters first human safety trials

NCT ID NCT05279755

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests whether a new drug, prosetin, is safe for people with ALS (Lou Gehrig's disease) and healthy volunteers. About 72 participants will receive either the drug or a placebo to check for side effects and how the drug moves through the body. The goal is to gather safety information before moving to larger trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • The Neuro - Montréal Neurological Institute-Hospital

    Montreal, Quebec, H3A 2B4, Canada

  • University Medical Center Utrecht

    Utrecht, Utrecht, 3584 CX, Netherlands

  • Worldwide Clinical Trials Early Phase Services

    San Antonio, Texas, 78217, United States